1. Opening Hook
While global chemical CEOs are still blaming geopolitics, tariffs, and their dog for weak demand, Tatva Chintan walked into Q3 FY26 and dropped a casual 53% revenue growth. No macro rant. No China dumping cry. Just execution.
This was one of those concalls where management didn’t sound hopeful—they sounded prepared. New plants being handed over. New chemistries already validated. New capex getting fast-tracked because waiting would mean missing the bus.
Agro is “bad,” pharma is “slow,” semiconductors are “early”—and yet Tatva is scaling all three simultaneously. Somewhere between photochlorination orders getting repeat business and semiconductor trials going ton-scale, it became clear this isn’t a recovery story anymore.
Read on. It gets more interesting when numbers start flexing and timelines stop being vague.
2. At a Glance
- Revenue ₹1,313 mn (+53% YoY): Demand woke up, Tatva was already dressed.
- EBITDA ₹255 mn (+261% YoY): Operating leverage finally clocked in.
- QoQ revenue +6%: Slow, steady, and far from panic mode.
- Pharma & Agro +86% YoY: New chemistries doing the heavy lifting.
- SDA QoQ -10%: Campaign business reminding analysts not to overreact.
- Electrolyte salts tiny but growing: Management quietly planting a future tree.
3. Management’s Key Commentary
“Engineering has handed over the plant to production today.”
(Translation: Execution > PowerPoint 😏)
“Chemical trials begin from 1st February.”
(This isn’t ‘expected commissioning’, this is calendar-marked execution.)
“We expect commercial use by first week of March.”
(No ‘maybe’, no ‘depending on conditions’.)
“We kept ourselves away from conventional chemistry.”
